Skip to main content

How is Cotempla XR-ODT different to other brands of methylphenidate?

Medically reviewed by Judith Stewart, BPharm. Last updated on Feb 14, 2023.

Official answer


Cotempla XR-ODT is the first once-daily, extended-release, orally disintegrating tablet (ODT) formulation of the stimulant methylphenidate.

This ODT formulation is designed to dissolve on the tongue without the need to swallow with water.

Cotempla XR-ODT (methylphenidate) was approved in June 2017 for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. It is not approved for use in adults.

Cotempla XR-ODT tablets are administered once daily in the morning.

Cotempla XR-ODT contains methylphenidate which is a Schedule II Controlled Substance, which means it has a high potential for abuse and dependence.

  • Cotempla XR-ODT must be stored in a safe place, preferably locked, to prevent misuse.
  • Cotempla XR-ODT must not be given to anyone else. Selling or giving away Cotempla XR-ODT may harm others and is against the law.
  • Any unused or expired Cotempla XR-ODT should be disposed of through a medicine take-back program if available.

There are many brands of methylphenidate on the U.S market with multiple dosage forms, including:

  • tablets (Ritalin)
  • extended-release tablets (Concerta, Methylin ER, Relexxii)
  • extended-release capsules (Adhansia XR, Aptensio XR, Jornay PM, Metadate CD, Ritalin LA)
  • extended-release chewable tablets (Quillichew ER)
  • extended-release orally disintegrating tablets (Cotempla XR-ODT)
  • transdermal system (Daytrana)
  • oral solution (Methylin)
  • powder for extended-release oral suspension (Quillivant XR)

For more information, see What are the brands of methylphenidate?

Related medical questions

Drug information

Related support groups